Evogene and Pure Capital Group have entered into a cooperation agreement to resolve differences and reconstitute the board of directors, replacing two current directors with nominees from Pure Capital Group.
Why it matters. The agreement provides long-term operational stability for Evogene, allowing it to focus on its AI-driven small-molecule discovery and optimization goals.
Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries
its goal of becoming a world leader in AI-driven small-molecule discovery and optimization for the pharmaceutical and ag-chemical industries
At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters.
the reconstituted Board will comprise seven directors, including four nominated by the Pure Capital Group
Evogene Ltd. (Nasdaq: EVGN ) (TASE: EVGN)
Under the terms of the Agreement, two current directors, Dr. Yael Margolin and Mr. Yoshinori Oikawa, who resigned from the Board will be replaced by Pure Capital Group nominees Dr.
REHOVOT, Israel , Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN ) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a…
